TolerMab TRX 4 - TolerRx

Drug Profile

TolerMab TRX 4 - TolerRx

Alternative Names: TolerMab anti-CD3 monoclonal antibody - TolerRx; TolerMab TRX4; TRX 4 - TolerMab - TolerRx

Latest Information Update: 01 Sep 2005

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TolerRx
  • Class Antihyperglycaemics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Type 1 diabetes mellitus

Most Recent Events

  • 01 Sep 2005 Discontinued - Preclinical for Autoimmune disorders in USA (unspecified route)
  • 01 Sep 2005 Discontinued - Preclinical for Type-1-diabetes-mellitus in USA (unspecified route)
  • 05 Jul 2003 Preclinical trials in Autoimmune disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top